Lilly/Daiichi Submit Prasugrel; Showdown With Plavix Timed For Second Half
Executive Summary
Lilly and Daiichi Sankyo plan to launch the antiplatelet drug prasugrel immediately after it is approved, supported by an extensive sales force including representatives from both companies
You may also be interested in...
AstraZeneca In The “Transparency” Era: An Interview With CEO David Brennan
If you visit AstraZeneca's offices in Washington, D.C., your name has to be on a list. After you get your badge, you show it at the elevator bank to a guard, who, in a throwback to operators of yore, steps inside with you to unlock the keypad and send you on your way
AstraZeneca In The “Transparency” Era: An Interview With CEO David Brennan
If you visit AstraZeneca's offices in Washington, D.C., your name has to be on a list. After you get your badge, you show it at the elevator bank to a guard, who, in a throwback to operators of yore, steps inside with you to unlock the keypad and send you on your way
The Year Ahead: Controversial NDAs Could Entangle FDA In ‘08; Where Are The Oncologics?
Looking ahead at FDA's review calendar for 2008, the agency will be wrestling with several enigmatic decisions as it considers applications for fibromyalgia and chronic fatigue syndrome, controversial diseases with nebulous definitions and diagnoses
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: